Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study
Paulo Rodrigues-Santos, Jani Sofia Almeida, Luana Madalena Sousa, Patrícia Couceiro, António Martinho, Joana Rodrigues, Ruben Fonseca, Manuel Santos-Rosa, Paulo Freitas-Tavares, José Manuel Casanova
TL;DR
This study examines immune responses in patients with refractory soft tissue sarcoma undergoing trabectedin therapy, identifying immune profiles linked to treatment outcomes.
Contribution
The study introduces comprehensive immune profiling to assess trabectedin therapy in refractory soft tissue sarcoma patients.
Findings
68.2% of patients achieved stable disease with trabectedin therapy.
PD patients showed reduced eosinophils and Th2 cells compared to SD patients.
Immune profiles correlated with RECIST1.1 criteria and therapy duration.
Abstract
Soft tissue sarcomas (STS) encompass over 50 histologic subtypes, representing more than 1% of solid tumors. Standard treatments include surgical resection and therapies such as anthracyclines or trabectedin for advanced cases, though challenges persist due to the tumor microenvironment’s complexity and limited immune profiling data. This study evaluates Trabectedin therapy in 22 refractory STS patients, analyzing progression-free survival (PFS) and immune responses. Immune monitoring included deep immunophenotyping (200+ parameters), gene expression profiling (103 genes), and soluble proteome analysis (99 analytes). Using RECIST1.1 criteria, 68.2% of patients achieved stable disease (SD), while 31.8% exhibited progression disease (PD). Therapy duration revealed 59.1% treated for less than 12 months (<12M) and 40.9% for 12 or more months (≥12M). A significant PFS improvement was…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSarcoma Diagnosis and Treatment · Lymphoma Diagnosis and Treatment · Immunotherapy and Immune Responses